China rejects patent linked to Gilead hepatitis C drug
0
NEW YORK/SHANGHAI (Reuters) - China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.